Andrew Dunn

Matthias zu Eicken, the Head of Housing and Urban Development Policy at Haus & Grund, with around 900,000 members, told Brussels Signal : “The German Government’s targets seem too ambitious for many homeowners.

Reshma Kewalramani is putting Vertex's $10 billion-plus balance sheet to work.

Over the last decade, one tech giant after another has tried to get into healthcare and failed.

A new startup aims to challenge Novo Nordisk and Eli Lilly's duopoly atop today's market for obesity drugs.

A star-studded mix of venture capitalists and scientists, backed by more than a billion dollars, is launching an ambitious biotech that aims to

In the 37 years since co-founding ARCH Venture Partners, Bob Nelsen has built a reputation for placing head-turning bets on ideas that carry huge amounts of risk and reward.

Earlier Tuesday, Endpoints News reported that former Stanford president Marc Tessier-Lavigne will lead one of biotech's biggest-ever startup

Regeneron is expanding its genetic medicine efforts and will work with California startup Mammoth Biosciences on gene-editing programs reaching parts of the human body beyond the liver, the companies announced Thursday.

“We're in a frothy time,” acknowledges Alexandra Snyder, the head of R&D at Generate:Biomedicines.

Chroma Medicine laid off an undisclosed number of employees earlier this week, as the privately held startup focuses its resources on moving its first epigenetic editors into human testing.